Coagulation Factor VII (FVII 401G>T) and glycoprotein Ib alpha (GP1BA Kozak -5C/T) gene variants as predictors of acute coronary syndrome in Indians: evidence from a case-control study.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2026-08-01 Epub Date: 2026-09-10 DOI:10.1080/17520363.2026.2729224

Sanchita Srivastava, Syed Tasleem Raza, Saliha Rizvi, Irshad Ahmad Wani, Zeba Siddiqi, Ale Eba, Farzana Mahdi

{"title":"Coagulation Factor VII (FVII 401G>T) and glycoprotein Ib alpha (GP1BA Kozak -5C/T) gene variants as predictors of acute coronary syndrome in Indians: evidence from a case-control study.","authors":"Sanchita Srivastava, Syed Tasleem Raza, Saliha Rizvi, Irshad Ahmad Wani, Zeba Siddiqi, Ale Eba, Farzana Mahdi","doi":"10.1080/17520363.2026.2729224","DOIUrl":null,"url":null,"abstract":"Background: Acute Coronary Syndrome (ACS) is a major cause of cardiovascular morbidity and mortality. Genetic variants affecting coagulation and platelet function, including Factor VII (FVII 401G>T) and GP1BA (Kozak -5 C/T), may influence ACS susceptibility.Methods: This hospital-based case-control study included 150 ACS patients and 150 age- and sex-matched healthy controls at Era's Lucknow Medical College and Hospital. Clinical, anthropometric, and lipid parameters were recorded, and FVII and GP1BA polymorphisms were genotyped using PCR-RFLP.Results: ACS patients had significantly higher BMI, blood pressure, LDL, VLDL, triglycerides, and total cholesterol, with lower HDL levels (all p<0.001). The FVII TT genotype (22.0% vs. 10.7%; OR=3.00, 95% CI: 1.48-6.10) and T allele (46.3% vs. 34.0%; OR=1.68, 95% CI: 1.21-2.33) were significantly associated with increased ACS risk. GP1BA genotypes and alleles showed no significant association with ACS. Neither polymorphism differed significantly across ACS subtypes.Conclusion: FVII 401G>T may be an important genetic susceptibility marker for ACS in the North Indian population, whereas GP1BA Kozak -5 C/T showed no significant association.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"771-778"},"PeriodicalIF":2.1000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13644624/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2026.2729224","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Acute Coronary Syndrome (ACS) is a major cause of cardiovascular morbidity and mortality. Genetic variants affecting coagulation and platelet function, including Factor VII (FVII 401G>T) and GP1BA (Kozak -5 C/T), may influence ACS susceptibility.

Methods: This hospital-based case-control study included 150 ACS patients and 150 age- and sex-matched healthy controls at Era's Lucknow Medical College and Hospital. Clinical, anthropometric, and lipid parameters were recorded, and FVII and GP1BA polymorphisms were genotyped using PCR-RFLP.

Results: ACS patients had significantly higher BMI, blood pressure, LDL, VLDL, triglycerides, and total cholesterol, with lower HDL levels (all p<0.001). The FVII TT genotype (22.0% vs. 10.7%; OR=3.00, 95% CI: 1.48-6.10) and T allele (46.3% vs. 34.0%; OR=1.68, 95% CI: 1.21-2.33) were significantly associated with increased ACS risk. GP1BA genotypes and alleles showed no significant association with ACS. Neither polymorphism differed significantly across ACS subtypes.

Conclusion: FVII 401G>T may be an important genetic susceptibility marker for ACS in the North Indian population, whereas GP1BA Kozak -5 C/T showed no significant association.

查看原文本刊更多论文

凝血因子VII （FVII 401G >t）和糖蛋白1b α (GP1BA Kozak -5C/T)基因变异是印度人急性冠状动脉综合征的预测因子：来自病例对照研究的证据

背景：急性冠脉综合征（ACS）是心血管疾病发病和死亡的主要原因。影响凝血和血小板功能的遗传变异，包括因子VII （FVII 401G>T）和GP1BA (Kozak -5 C/T)，可能影响ACS的易感性。方法：本以医院为基础的病例对照研究纳入了Era勒克瑙医学院和医院的150例ACS患者和150例年龄和性别匹配的健康对照。记录临床、人体测量和脂质参数，并使用PCR-RFLP对FVII和GP1BA多态性进行基因分型。结果：ACS患者BMI、血压、LDL、VLDL、甘油三酯和总胆固醇均显著增高，HDL水平均较低。结论：FVII 401G>T可能是北印度人群ACS的重要遗传易感性标志物，而GP1BA Kozak -5 C/T与ACS无显著相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.